Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02271711|
Recruitment Status : Recruiting
First Posted : October 22, 2014
Last Update Posted : May 23, 2019
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Childhood Medulloblastoma Recurrent Ependymoma Recurrent Medulloblastoma||Other: Laboratory Biomarker Analysis Biological: Natural Killer Cell Therapy||Phase 1|
I. To establish the safety, feasibility, efficacy, and maximum tolerated dose (MTD) of administering autologous natural killer (NK) cells that have been propagated ex vivo with artificial antigen-presenting cells (aAPC) and administered directly into the ventricle in recurrent /refractory malignant posterior fossa tumors.
I. To assess the antitumor activity based on imaging and cytology of autologous NK cell locoregional administration directly into the lateral or fourth ventricle.
II. To determine the persistence of adoptively-transferred expanded NK cells (as performed with excess NK cells, via optional correlative studies).
III. Determine the immunophenotype and function of expanded NK cells. IV. Determine the overall response of medulloblastoma to NK-cell therapy. V. Correlate NK cell persistence, phenotype, and function with overall response.
OUTLINE: This is a dose-escalation study.
Patients receive autologous expanded NK cells intravenously (IV) into the ventricle over 3 minutes once weekly on weeks 1-3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may continue treatment at the discretion of the treating physician if pseudo-progression or benefit of slowed progression is suspected.
After completion of study treatment, patients are followed up within 30 days.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I Study of Intraventricular Infusions of Autologous Ex Vivo-Expanded NK Cells in Children With Recurrent/Refractory Malignant Posterior Fossa Tumors of the Central Nervous System. NOAH's (New Opportunity, Advancing Hope) Protocol|
|Actual Study Start Date :||March 17, 2015|
|Estimated Primary Completion Date :||March 30, 2020|
|Estimated Study Completion Date :||March 30, 2020|
Experimental: Treatment (autologous ex vivo-expanded NK cells)
Patients receive autologous expanded NK cells IV into the ventricle over 3 minutes once weekly on weeks 1-3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may continue treatment at the discretion of the treating physician if pseudo-progression or benefit of slowed progression is suspected.
Other: Laboratory Biomarker Analysis
Biological: Natural Killer Cell Therapy
Given autologous ex-vivo expanded NK cells IV
- Maximum tolerated dose (MTD) of natural killer (NK) cells [ Time Frame: 4 weeks ]Defined as the highest dose studied in which 6 patients have been treated at most 1 patient with dose limiting toxicities are observed. Toxicities will be summarized by tabulation in terms of type, grade and attribution for each dose level of each group of patients studied at the end of the trial.
- Activation status of NK cells [ Time Frame: Up to 30 days after the last infusion in course 3 ]Determined by flow-based activation assay determining cluster of differentiation (CD)107a expression of NK cells in response to standardized targets.
- Persistence of NK cells [ Time Frame: Up to 30 days after the last infusion in course 3 ]Peripheral blood and cerebrospinal fluid (CSF) will be obtained before therapy, during the NK cell treatment period, and after NK cell treatment.
- Function of NK cells [ Time Frame: Up to 30 days after the last infusion in course 3 ]Assessed by cell lysis of standardized targets.
- Response of medulloblastoma to NK cells [ Time Frame: Up to 30 days after the last infusion in course 3 ]Antitumor activity will be described for each group of patients based on imaging and cytology. Clinical response will be correlated with NK cell persistence in vivo, cytokine levels, and expression of activation markers.
- Feasibility of NK cell manufacturing [ Time Frame: Up to 12 weeks ]If analysis shows < 50% successful product generation after at least six patients have been enrolled, the study will be temporarily stopped to address possible changes in the manufacturing process.
- Feasibility of delivering NK cells [ Time Frame: Up to 12 weeks ]Therapy will be considered feasible if at least 2/3 of subjects treated receive at least 21 of the planned 27 NK cell infusions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02271711
|Contact: Soumen Khatuafirstname.lastname@example.org|
|United States, Texas|
|M D Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Soumen Khatua 713-792-3280|
|Principal Investigator: Soumen Khatua|
|Principal Investigator:||Soumen Khatua||M.D. Anderson Cancer Center|